Nuclear factor NF-kappa-B p50 subunit (NF-κB p50)

The Nuclear factor NF-kappa-B p50 subunit is the active, mature fragment derived from proteasome-mediated cleavage of the precursor p105 (NF-κB1)[1][2][8]. It is a member of the NF-κB protein family, which functions as inducible transcription factors controlling expression of genes involved in immune response, inflammation, cell survival, and development[3][4][5]. The p50 subunit most commonly functions as an obligate dimer, forming homodimers (transcriptional repressors) or heterodimers with RelA/p65 (transcriptional activators)[1][3][8]. NF-κB activation is tightly controlled via the IκB family of inhibitory proteins and is central to regulating rapid cellular responses to stress, infection, and cytokine signaling. Dysregulation of NF-κB, particularly the p50 subunit, is implicated in the pathogenesis of cancers, inflammatory diseases, neurodegenerative disorders, and cardiovascular disease[4][5]. Therapeutic targeting of NF-κB p50 aims to modify these disease processes, but systemic blockade poses significant safety and immunological risks.

Other names

NF-κB1 (p50)p50NF-kappa-B DNA-binding factor KBF1NFKB1Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1

Mechanism of action for drugs targeting NF-κB p50 includes inhibition of its transcriptional activity by targeting dimerization or DNA binding, blocking proteasome-mediated processing of its inhibitory precursor, preventing nuclear translocation via stabilization of IκB inhibitors, and targeting upstream activators (e.g., IKK complex inhibition).